Evaluating GNC-077 for advanced breast cancer and solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, multicenter, dose-escalation phase I clinical study aimed at assessing the safety, tolerability, pharmacokinetics, and preliminary efficacy of GNC-077 in patients with locally advanced or metastatic breast cancer and other solid tumors. The study will involve participants who have measurable lesions and will evaluate the antitumor activity of the treatment. The trial will also include cohort expansions to gather more data on the drug's effects across different patient groups.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Able to understand the informed consent form, voluntarily participate in and sign the informed consent form;
2. Gender is not limited;
3. Age: ≥18 years old and ≤75 years old (stage Ia); ≥18 years old (stage Ib);
4. Locally advanced or metastatic breast cancer and other solid tumors;
5. Must have at least one measurable lesion that meets the RECIST v1.1 definition;
6. Have archived primary or recurrent tumor tissue specimens that can be submitted for central review;
7. ECOG ≤1;
8. The expected survival time as judged by the investigators was ≥3 months;
9. Bone marrow function, renal function and liver function should meet the requirements;
10. Coagulation function: fibrinogen ≥1.5g/L; Activated partial thromboplastin time (APTT) ≤1.5×ULN; Prothrombin time (PT) ≤1.5×ULN;
11. Fertile female subjects or male subjects with fertile partners must use highly effective contraception from 7 days before the first dose until 12 weeks after the last dose. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose;
12. Subjects were able and willing to comply with protocol-specified visits, treatment plans, laboratory tests, and other study-related procedures.

Exclusion Criteria:

1. Chemotherapy, biological therapy, immunotherapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oral drugs such as fluorouracil;
2. Patients with active infection requiring intravenous antibiotics who did not complete treatment within 1 week before enrollment, except prophylactic antibiotics for puncture or biopsy;
3. Positive human immunodeficiency virus antibody, active tuberculosis, active hepatitis B virus infection or hepatitis C virus infection;
4. No reduction in toxicity from previous antineoplastic therapy to grade I as defined in CTCAE, version 5.0, or to the level specified in the inclusion criteria;
5. Patients at risk for active autoimmune disease or with a history of autoimmune disease may have central nervous system involvement;
6. Pulmonary disease defined as ≥ grade 3 according to NCI-CTCAE v5.0; A history of ILD requiring steroid therapy, or current ILD or grade ≥2 radiation pneumonitis;
7. Patients with previous allogeneic hematopoietic stem cell transplantation or organ transplantation;
8. Had a history of severe cardiovascular and cerebrovascular diseases;
9. Patients had or had thrombotic events such as deep vein thrombosis, arterial thrombosis and pulmonary embolism within 6 months before screening;
10. Brain parenchymal metastases and/or meningeal metastases or spinal cord compression, excluding stable and asymptomatic brain parenchymal metastases;
11. Uncontrolled pleural effusion with clinical symptoms who were judged by the investigator to be ineligible for enrollment;
12. Poorly controlled hypertension (systolic blood pressure \> 150 mmHg or diastolic blood pressure \> 100 mmHg);
13. Who had participated in a clinical trial of an unmarketed drug within 4 weeks before the study dose (counted as the end of the last dose);
14. Had received a live vaccine within 4 weeks before the trial dose;
15. Other circumstances that the investigator deemed inappropriate for participation in the trial.

Where it's running

• Cancer Hospital Chinese Academy of Medical Sciences
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Binghe Xu, PHD — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Study coordinator: Sa Xiao, PHD
• Email: xiaosa@baili-pharm.com
• Phone: 15013238943

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SI-B036 in locally advanced or metastatic breast cancer and other solid tumors

  Scientists are testing SI-B036 to see if it is safe and tolerable in adults with advanced breast cancer or other solid tumors and to get early signals of whether it might help.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07753226

• Neoadjuvant prehabilitation to improve physical and mental recovery for people with solid tumors

  This trial tests whether a supervised exercise program plus structured psycho-oncological support before surgery or radiotherapy helps adults with solid tumors stay fitter and feel better than standard care.

  Recruiting University Hospital Muenster · Münster, North Rhine-Westphalia · NCT07464457

• OCT-598 for advanced solid tumors

  This trial tests whether OCT-598, by itself or with docetaxel, is safe and to find the best dose for adults with advanced solid tumors who have limited standard treatment options.

  Recruiting at 2 sites Phase 1 Oscotec Inc. · Goyang-si and 2 other locations · NCT07358806

• TER-2013 for advanced solid tumors with AKT/PI3K/PTEN pathway changes

  This trial tests whether TER-2013, alone or with fulvestrant, is safe and can help people with advanced breast, ovarian, endometrial, lung, or head-and-neck cancers that have AKT/PI3K/PTEN pathway alterations.

  Recruiting at 20 sites Phase 1/2 Terremoto Biosciences Inc. · Duarte, California and 24 other locations · NCT07109726

• Using brodalumab to treat immune-related side effects from cancer therapy

  This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06673329

• Imaging study using two antibody fragments in patients with solid tumors

  This study is testing two special antibody fragments in people with solid tumors to see how well they target cancer cells and how they move through the body.

  Recruiting Early Phase 1 Var2 Pharmaceuticals · Groningen, Provincie Groningen · NCT06645808

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.